Resource table {#S1}
==============

  --------------------------------------- --------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        CDMLe001-A
  Alternative name(s) of stem cell line   H1-*RB1*(E16)^−/+^
  Institution                             The University of Texas Health Science Center at Houston
  Contact information of distributor      <dung-fang.lee@uth.tmc.edu>
  Type of cell line                       Human embryonic stem cell line
  Origin                                  hESC line H1 (WA01) from WiCell Institute
  Additional origin info                  Sex: Male (46, XY)
  Cell Source                             Human blastocyst
  Clonality                               Clonal
  Method of reprogramming                 N/A
  Genetic Modification                    Yes
  Type of Modification                    Deletion of 50 bp in *RB1* exon 16.
  Associated disease                      Hereditary retinoblastoma
  Gene/locus                              13q14.1-14.2; *RB1* exon 16
  Method of modification                  CRISPR/Cas9 nickase
  Name of transgene or resistance         None
  Inducible/constitutive system           None
  Date archived/stock date                11/7/2017
  Cell line repository/bank               None
  Ethical approval                        Cell lines were used according to institutional guidelines. UTHealth approval number: SCRO-16-01
  --------------------------------------- --------------------------------------------------------------------------------------------------

Resource utility {#S2}
================

We generate a human embryonic stem cell (hESC) line with heterozygous *RB1* deletion to facilitate the modeling of the cancer etiology of hereditary retinoblastoma.

Resource details {#S3}
================

Hereditary retinoblastoma patients commonly carry a heterozygous *RB1* mutation or deletion ([@R3]). Random sporadic damage to the remaining normal copy of RB1 in retinal cells initiates development of retinoblastoma. To provide a useful lab resource for scientists investigating hereditary retinoblastoma, we generated a heterozygous *RB1* deletion hESC line by targeting exon 16 of the *RB1* gene using the CRISPR/Cas9 nickase gene editing system ([Fig. 1A](#F1){ref-type="fig"}, the Cas9/sgRNA target sites are underlined and *RB1* introns and exons are presented in lowercase and uppercase, respectively).

hESC H1 cells were transfected with pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A) (Puro^R^) plasmids carrying sgRNAs targeting exon 16 of the *RB1* gene. Electroporated cells were selected by puromycin. The puromycin-resistant clones were picked up, isolated, and expanded. The *RB1* targeted regions were analyzed by PCR to demonstrate that only one allele was deleted ([Fig. 1B](#F1){ref-type="fig"}). Primers surrounding exon 16 (amplifying both the wild-type and deleted alleles) were designed and the genetic region amplified by PCR and examined by Sanger sequencing. The mono-allelic 50-nucleotide-deletion was confirmed in the deleted allele, while the other allele retained its wild-type sequence ([Fig. 1C](#F1){ref-type="fig"}). A premature stop codon was also noted in *RB1* exon 17 in the allele with a 50-nucleotide-deletion in one of two heterozygous *RB1* deletion hESC clones obtained and submitted for further characterization.

The H1-*RB1*(E16)^−/+^ line maintains a classical tightly packaged dome-shape hESC morphology and expresses high levels of pluripotency transcription factors (NANOG and OCT4), hESC surface markers (SSEA4 and TRA-1-81) as well as alkaline phosphatase (AP) ([Fig. 1D](#F1){ref-type="fig"}, scale bar 100 μm). The expression of pluripotency genes (*NANOG*, *OCT4*, *SOX2*, *DPPA4*, and *REX1*) in the H1-*RB1*(E16)^−/+^ line was compared to the levels in parental H1 cells by quantitative real-time PCR. PCR reactions are normalized to *GAPDH*. The expression levels of all five pluripotency genes in the H1-*RB1*(E16)^−/+^ line were comparable to those in parental H1 cells ([Fig. 1E](#F1){ref-type="fig"}, error bars indicate ± SEM of triplicates). Immunoblotting results suggested that RB1 expression is lower in the H1-*RB1*(E16)^−/+^ line than in parental H1 cells ([Fig. 1F](#F1){ref-type="fig"}). PCR-based mycoplasma detection assay confirmed the cell line is mycoplasma-free ([Fig. 1G](#F1){ref-type="fig"}). Karyotype analysis suggested that the H1-*RB1*(E16)^−/+^ line does not contain any chromosomal abnormality ([Fig. 1H](#F1){ref-type="fig"}). Additionally, the short tandem repeat (STR) profile of H1-*RB1*(E16)^−/+^ cells was identical to that of their parental H1 cells ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Furthermore, H1-*RB1* (E16)^−/+^ cells maintained the potential to differentiate into all three germ layers as determined by their ability to differentiate to SOX17 and HNF4A-positive hepatic progenitor cells (HPCs, endodermal lineage) ([Fig. 1I](#F1){ref-type="fig"}, scale bar 100 μm), CD73 and CD105-positive mesenchymal stem cells (MSCs, mesodermal lineage) ([Fig. 1J](#F1){ref-type="fig"}, scale bar 100 μm) as well as PAX6 and NESTIN-positive neural progenitor cells (NPCs, ectodermal lineage) ([Fig. 1K](#F1){ref-type="fig"}, scale bar 100 μm). In summary, the H1-*RB1*(E16)^−/+^ line is pluripotent and demonstrates a normal karyotype. The H1-*RB1*(E16)^−/+^ line provides a valuable cell resource to study the cancer etiology of hereditary retinoblastoma.

Materials and methods {#S4}
=====================

Maintenance of hESCs {#S5}
--------------------

hESCs were maintained on Matrigel (Corning)-coated plates with StemMACS^™^iPS-Brew XF (Miltenyi Biotec). StemMACS^™^ Passaging Solution XF (Miltenyi Biotec) was used to passage hESCs and Rock inhibitor (Calbiochem) was utilized to improve cell survival rate during replating.

Generation of RB1 heterozygous deletion hESC line by CRIPSR/Cas9 nickase gene editing methodology {#S6}
-------------------------------------------------------------------------------------------------

A CRISPR guide targeting exon 16 of RB1 was designed using CRISPR Design website (<http://crispr.mit.edu>). Two sgRNAs (TTAGCAAACTTCTGAGTGAC and TTTATTGGCGTGCGCTCTTG) targeting exon 16 of *RB1* gene were selected and cloned into pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A)(Puro^R^), respectively to generate the guide plasmids. For electroporation, 10^7^ cells were re-suspended with 0.6 ml Embryo Max Electroporation Buffer (Millipore), mixed with CRISPR/Cas9 nickase plasmids (25 μg each) and electroporated at 300 V/500 μF in a BIO-RAD Gene Pulser Xcell System. Following electroporation, cells were immediately dispensed into 10 cm MEF-coated plates in hESC medium (DMEM/F12 (Corning) with 20% KnockOut Serum replacement (Life Technologies), 1% Gibco GlutaMax (Life Technologies), 1% NEAA (Corning), 0.0007% β-mercaptoethanol (Sigma) and 10 ng/ml FGF2 (EMD Millipore)) supplemented with 10 μM ROCK inhibitor. After 48 h recovery, cells were treated with 1 μM puromycin (Sigma) for 48 h and then maintained in regular hESC medium for colony growth. The isolated genomic DNA from individual colonies was used for clonal identification by PCR using a *RB1* exon 16 specific primer set (forward: 5′-TCTGTTTCAGGAAGAAGAACGAT-3′; reverse: 5′-ACCATGGAGGTTACAGCAGTG-3′). The PCR fragments of wild-type and deletion of *RB1* exon 16 were examined by Sanger sequencing.

Quantitative real-time PCR {#S7}
--------------------------

Total mRNA was isolated using TRIzol (Invitrogen) following the manufacturer's instructions. 1 μg of RNA was used for reverse transcription. Real-time PCR analysis was performed on a CFX96 machine (Bio-Rad) using the SYBR Green PCR Master Mix (Bio-Rad). The PCR reaction consisted of 10 μl SYBR Green PCR Master Mix, 1 μl of 10 μM forward and reverse primers, and 1 μl of 3-times diluted template cDNA in a total volume of 20 μl. Samples were analyzed in triplicate and normalized to GAPDH expression. The primer sequences are shown in [Table 1](#T1){ref-type="table"}.

In vitro differentiation {#S8}
------------------------

*In vitro* differentiation of H1-*RB1*(E16)^−/+^ cells to HPCs, MSCs, and NPCs was performed by well-defined differentiation protocols described previously ([@R1]; [@R4]; [@R5]). For cell characterization, SOX17 (R&D Systems) and HNF4A (Cell Signaling Technology) were used for HPCs, CD105 (Thermo Fisher Scientific) and CD73 (BD Biosciences) were used for MSCs, and PAX6 (BioLegend) and NESTIN (BioLegend) were used for NPCs.

Immunofluorescent staining and immunoblotting {#S9}
---------------------------------------------

H1-*RB1*(E16)^−/+^cells or differentiated cells were fixed with 4% paraformaldehyde in PBS for 10 min at room temperature, blocked with 10% serum in 0.1% PBST for 1 h and incubated with the indicated primary antibodies ([Table 2](#T2){ref-type="table"}) overnight. Cells were then washed with PBST, incubated with corresponding secondary antibodies for 1 h at room temperature, and detected by Leica DMi8. Immunoblotting was performed as described ([@R2]).

Mycoplasma test {#S10}
---------------

PCR mycoplasma test kit was used according to the manufacturer's instructions (abm G238).

Karyotype analysis and STR analysis {#S11}
-----------------------------------

The G-banding karyotype was performed by The T. C. Hsu Molecular Cytogenetics Facility in The University of Texas M.D. Anderson Cancer Center. Twenty metaphase chromosome spreads were analyzed with G-band resolution of 450--500. STR analysis for parent cell authentication was performed by the Characterized Cell Line Core Facility in The University of Texas M.D. Anderson Cancer Center. 14 STR loci were compared using the Promega Powerplex 16 HS kit. Fragments were amplified by PCR for further analysis.

[Supplementary data](#SD1){ref-type="supplementary-material"} to this article can be found online at <https://doi.org/10.1016/j.scr.2018.01.021>.

Supplementary Material {#S12}
======================
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![Generation and characterization of the *RB1* heterozygous knockout hESC line H1-*RB1*(E16)^−/+^. (A) Schematic overview of the gene targeting strategy to knockout *RB1* exon 16 using CRISPR/Cas9 nickase. *RB1* introns and exons are shown in lowercase and uppercase, respectively. The sgRNA target sites are underlined. (B) PCR confirms the deletion of the *RB1* exon 16 in the H1-*RB1*(E16)^−/+^ line. (C) Sanger sequencing reveals the heterozygous deletion of the *RB1* exon16. (D) The H1-*RB1*(E16)^−/+^ line expresses hESC pluripotency factors (NANOG and OCT4) and hESC surface markers (SSEA4 and TRA-1-81), and exhibits positive AP activity. Scale bar = 100 μm. (E) qRT-PCR reveals the expression of endogenous human NANOG, SOX2, OCT4, DPPA4, and REX1in H1-*RB1*(E16)^−/+^ line. PCR reactions are normalized to GAPDH and plotted relative to expression levels in human H1 ESCs. Error bars indicate ± SEM of triplicates. (F) The H1-*RB1*(E16)^−/+^ line presents the lower expression of RB1 protein. (G) The H1-*RB1*(E16)^−/+^ line is mycoplasma-free. (H) The H1-*RB1*(E16)^−/+^ line shows normal karyotype. (I--K) The H1-*RB1*(E16)^−/+^ line maintains pluripotency. Immunofluorescence staining reveals that H1-*RB1*(E16)^−/+^ line is capable of differentiating to endodermal (HPCs), mesodermal (MSCs) and ectodermal (NPCs) lineages. Scar bar = 100 μm.](nihms957155f1){#F1}

###### 

Characterization and validation.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification                        Test                                   Result                                                                                         Data
  ------------------------------------- -------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Morphology                            Photography                            Normal                                                                                         [Fig. 1](#F1){ref-type="fig"} panel D

  Phenotype                             Immunocytochemistry\                   NANOG, OCT4, SSEA4, TRA-1-81 and AP-positive.\                                                 [Fig. 1](#F1){ref-type="fig"} panel D\
                                        RT-qPCR                                Comparable of *NANOG*, *OCT4*, *SOX2*, *DPPA4*, and *REX1* expression with H1.                 [Fig. 1](#F1){ref-type="fig"} panel E

  Genotype                              Karyotype (G-banding) and resolution   46 XY\                                                                                         [Fig. 1](#F1){ref-type="fig"} panel H
                                                                               Resolution: 450--500                                                                           

  Identity                              Microsatellite PCR (mPCR) OR\          N/A\                                                                                           N/A\
                                        STR analysis                           14/14 sites matched                                                                            [Supplementary Table S1](#SD1){ref-type="supplementary-material"}

  Mutation analysis (IF APPLICABLE)     Sequencing\                            Heterozygous deletion of 50 bp in *RB1* exon 16.\                                              [Fig. 1](#F1){ref-type="fig"} panel B\
                                        Southern Blot OR WGS                   N/A                                                                                            N/A

  Microbiology and virology             Mycoplasma                             Mycoplasma test shows negative.                                                                [Fig. 1](#F1){ref-type="fig"} panel G

  Differentiation potential             Directed *in vitro* differentiation    Expression of SOX17 and HNF4A in HPCs, CD105 and CD166 in MSCs, and PAX6 and NESTIN in NPCs.   [Fig. 1](#F1){ref-type="fig"} panel I, J, and K

  Donor screening (OPTIONAL)            HIV 1 + 2 Hepatitis B, Hepatitis C     N/A                                                                                            N/A

  Genotype additional info (OPTIONAL)   Blood group genotyping\                N/A\                                                                                           N/A\
                                        HLA tissue typing                      N/A                                                                                            N/A
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagents details.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibodies used for immunocytochemistry                                                                                                                    
  ----------------------------------------- -------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------
  Pluripotency markers                      Goat anti-NANOG                                    1:400                                                         R and D Systems Cat\# AF1997 RRID:AB_355097

  Pluripotency markers                      Rabbit anti-OCT4                                   1:250                                                         Santa Cruz Biotechnology Cat\# sc-9081 RRID:AB_2167703

  Pluripotency markers                      Mouse anti-SSEA4                                   1:200                                                         R and D Systems\
                                                                                                                                                             FA1435P-025

  Pluripotency markers                      Mouse anti-TRA-1-85                                1:400                                                         R and D Systems Cat\# FAB3195A RRID:AB_663789

  Differentiation markers                   Anti-CD105                                         1:400                                                         Thermo Fisher Scientific Cat\# 12-1057-42 RRID:AB_1311123

  Differentiation markers                   Anti-CD73                                          1:400                                                         BD Biosciences Cat\# 550257 RRID:AB_393561

  Differentiation markers                   Rabbit\                                            1:1000                                                        Cell Signaling Technology Cat\# 3113S RRID:AB_2295208
                                            anti-HNF4a                                                                                                       

  Differentiation markers                   Goat anti-SOX17                                    1:500                                                         R and D Systems Cat\# AF1924 RRID:AB_355060

  Differentiation markers                   Rabbit anti-PAX6                                   1:200                                                         BioLegend Cat\# 901301 RRID:AB_2565003

  Differentiation markers                   Mouse anti-NESTIN                                  1:200                                                         BioLegend Cat\# 655102 RRID:AB_2562023

  RB1 (Western Blot)                        Mouse anti-RB1                                     1:250                                                         BD Biosciences Cat\# 554136 RRID:AB_395259

  Secondary antibodies                      Goat anti-rabbit IgG(Alexa Fluor 488 conjugate)    1:1000                                                        Jackson ImmunoResearch Labs Cat\# 111-545-144 RRID:AB_2338052

  Secondary antibodies                      Donkey Anti-Goat IgG (Alexa Fluor488 conjugate)    1:1000                                                        Jackson ImmunoResearch Labs Cat\# 705-545-003 RRID:AB_2340428

  Secondary antibodies                      Donkey Anti-Mouse IgG (Alexa Fluor488 conjugate)   1:1000                                                        Jackson ImmunoResearch Labs Cat\# 715-545-150 RRID:AB_2340846

  Secondary antibodies                      Donkey Anti-Rabbit IgG (Cy3 conjugate)             1:1000                                                        Jackson ImmunoResearch Labs Cat\# 711-165-152 RRID:AB_2307443

  Secondary antibodies                      Donkey Anti-Rabbit IgG (Cy5 conjugate)             1:1000                                                        Jackson ImmunoResearch Labs Cat\# 711-175-152 RRID:AB_2340607

  Primers                                                                                                                                                    

                                                                                                                                                             

                                            Target                                             Forward/reverse primer (5′--3′)                               

                                                                                                                                                             

  Pluripotency markers (qPCR)               OCT4                                               AACCTGGAGTTTGTGCCAGGGTTT/TGAACTTCACCTTCCCTCCAACCA             

  Pluripotency markers (qPCR)               SOX2                                               AGAAGAGGAGAGAGAAAGAAAGGGAGAGA/GAGAGAGGCAAACTGGAATCAGGATCAAA   

  Pluripotency markers (qPCR)               NANOG                                              TTTGTGGGCCTGAAGAAAACT/AGGGCTGTCCTGAATAAGCAG                   

  Pluripotency markers (qPCR)               DPPA4                                              GACCTCCACAGAGAAGTCGAG/TGCCTTTTTCTTAGGGCAGAG                   

  Pluripotency markers (qPCR)               REX1                                               GCCTTATGTGATGGCTATGTGT/ACCCCTTATGACGCATTCTATGT                

  House-keeping genes (qPCR)                GAPDH                                              CCACTCCTCCACCTTTGAC/ACCCTGTTGCTGTAGCCA                        

  Targeted mutation analysis/sequencing     RB1 exon16                                         TTCTTTTTATAGAAGTAAGTATTTTATAATC/CTCAAAGGTCTTCGGAGGGA          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
